Prevalence and molecular epidemiology of carbapenem resistance in Asia: A systematic review and meta-analysis DOI Creative Commons
Nishadi Jayathilaka,

Shehana Denagamagei,

Dilini Nakkawita

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Дек. 18, 2024

Abstract Background Carbapenems are a group of last-resort antibiotics used to treat serious life-threatening infections. The emergence resistance carbapenems is major public health threat. However, comprehensive information on the prevalence and molecular epidemiology carbapenem (CR) among Asian countries lacking. Therefore, we aimed determine CR associated determinants quantitatively countries. Methods In this systematic review meta-analysis, searched published reports in electronic databases such as PubMed, ScienceDirect, Cochrane Library Web Science from 1st January 2014 31st 2024 that fulfilled these criteria; original studies conducted countries, including clinical isolates, English. Data extraction risk bias assessment was performed by two independent reviewers. pooled with 95% confidence interval (CI) computed random effects model. Heterogeneity across determined I2. geographical location, income level, publication year sample size were analysed subgroups. Results We identified 2518 eligible studies, which 37 assessed data 10,433 patients. (PPr) 31.3% (95% CI; 0.22 0.40; I2 = 99.9%; P 0.00). A trend incidence observed 2004–2023, PPr values ranging 7.4–50.6%. Variation distribution genes observed, blaNDM being most common gene, followed blaOXA blaKPC. Univariate meta–regression analysis indicated did not significantly affect heterogeneity (p < 0.05). Conclusion results suggest surveillance essential reduce burden antibiotic resistance. Mitigating impact infections will safeguard efficacy for future generations further dissemination genes. Systematic registration: This registered at PROSPERO (CRD42024515806).

Язык: Английский

Prevalence of carbapenem-resistant gram-negative bacteria among neonates suspected for sepsis in Africa: a systematic review and meta-analysis DOI Creative Commons
Assefa Sisay, Zelalem Asmare, Getinet Kumie

и другие.

BMC Infectious Diseases, Год журнала: 2024, Номер 24(1)

Опубликована: Авг. 18, 2024

The emergence and rapid spread of gram-negative bacteria resistant to carbapenems among newborns is concerning on a global scale. Nonetheless, the pooled estimate carbapenem that cause neonatal sepsis in developing nations remains unknown. Thus, this study aimed determine combined prevalence African who were suspected having sepsis.

Язык: Английский

Процитировано

4
Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis DOI Creative Commons
Jomana Al Hroot,

Joshua A. Reeder,

Xuanzhen Yuan

и другие.

Antimicrobial Agents and Chemotherapy, Год журнала: 2025, Номер unknown

Опубликована: Май 5, 2025

ABSTRACT Fosfomycin, a broad-spectrum antibiotic used for uncomplicated cystitis, represents potential promising candidate in combating resistant pneumonia. To facilitate the transition of fosfomycin to broader indications, including pneumonia, minimal physiologically based pharmacokinetics (m-PBPK) model was developed on data from plasma, epithelial lining fluid (ELF), and alveolar macrophages (AMs) obtained 37 healthy participants recently completed intrapulmonary PK study. Utilizing this mechanistic m-PBPK enabled us predict drug concentrations at infection site pneumonia patients, taking into consideration pathophysiological changes occurring during infection. Our prediction shows that reduced, while plasma levels remain unchanged. Monte Carlo simulations were conducted evaluate probability target attainment (PTA) various dosing regimens infused over 1 h against major hospital-acquired pathogens ELF. PTA analysis suggested if are appropriate efficacy indicator, dose 4 g q8h is sufficient Pseudomonas aeruginosa Staphylococcus aureus infections. However, ELF more accurate only effective S. For P. 6 recommended, with an even higher 8 necessary patients. In conclusion, our provides critical insights treatment, guiding clinical study design. Furthermore, it serves as platform other antibiotics.

Язык: Английский

Процитировано

0
The magnitude of MDR carbapenemase-producing Enterobacteriaceae isolates and associated factors among hospitalized patients of Northeast Ethiopia DOI Creative Commons
Assefa Sisay, Chalie Mulugeta

JAC-Antimicrobial Resistance, Год журнала: 2025, Номер 7(3)

Опубликована: Апрель 29, 2025

Abstract Background Currently, carbapenemase-producing Enterobacteriaceae (CPE) are becoming a global public health threat. Infections caused by these bacteria limit treatment options and associated with high morbidity mortality. This study aimed to assess the prevalence of CPE identify risk factors. Methods A hospital-based cross-sectional was conducted from June August 2023. Clinical samples were cultured, species identification performed using standard biochemical tests. Antimicrobial susceptibility testing done, modified carbapenem inactivation method employed confirm carbapenemase production. Data entered Epi analysed SPSS. Results From total 143 isolates, most commonly identified Escherichia coli (62 43.4%) Klebsiella pneumoniae (39 27.3%). The highest level resistance against ampicillin (138 96.5%), whereas lowest observed meropenem (19 13.3%). Overall, 123 isolates (86.0%) classified as MDR. carbapenem-resistant (CRE) 5.7% 8.1%, respectively. K. E. common producers. Chronic underlying disease, consuming raw vegetables, lack regular hand-washing habits before meals showed adjusted odds ratios 7.9 (95% CI 1.9–31.5), 11 3.4–40) 8.0 1.7–85), respectively, showing significant association. Conclusions underscores need for urgent infection control measures. Implementing antimicrobial stewardship, strengthening measures, further molecular studies vital combating this problem.

Язык: Английский

Процитировано

0
Surge of branded generics and antimicrobial resistance: analyzing the antibiotic market dynamics in Pakistan through the WHO essential medicines and AWaRe lens DOI Creative Commons

Saad Abdullah,

Zikria Saleem, Brian Godman

и другие.

Expert Review of Anti-infective Therapy, Год журнала: 2025, Номер unknown

Опубликована: Май 26, 2025

Access to safe and effective antibiotics is crucial in low- middle-income countries (LMICs) coupled with reducing overuse reduce antimicrobial resistance (AMR). We sought systematically analyze the extent of branded generic Pakistan particularly Watch given concerns AMR Pakistan. Data on registered was collected from Drug Regulatory Authority (DRAP) Pharmaguides. 257 were analyzed using AWaRe classification. Of these, 99 including 91 single entities 8 combinations, 6,025 brands 14,076 presentations. Distribution across categories included - 37, 56, Reserve 6. Cephalosporins (2186 brands, 6447 presentations) Quinolones (1333 2586 are most prevalent, Ciprofloxacin (393 1158 leading brand presentation counts. 6 WHO Essential Medicines List lacked Pakistan, while many available not framework. Conclusion: Extensive availability generics poses a serious risk, exacerbated by current misuse antibiotics. Improving regulatory frameworks strengthening stewardship critical along addressing uncontrolled registration DRAP.

Язык: Английский

Процитировано

0
Meropenem-Induced Cross-Protection in Salmonella enterica Resistant Variants: Insights from Adaptive Laboratory Evolution and Whole Genome Sequencing DOI Creative Commons
Ruthchelly Tavares da Silva,

Ivo García-Penas,

Laura Espina

и другие.

Food Microbiology, Год журнала: 2025, Номер unknown, С. 104823 - 104823

Опубликована: Июнь 1, 2025

Язык: Английский

Процитировано

0
Prevalence and molecular epidemiology of carbapenem resistance in Asia: a systematic review and meta-analysis DOI Creative Commons
Nishadi Jayathilaka,

Sashini Shehana,

Dilini Nakkawita

и другие.

Systematic Reviews, Год журнала: 2025, Номер 14(1)

Опубликована: Июнь 5, 2025

Язык: Английский

Процитировано

0
Molecular detection of OXA-48 and NDM-1 carbapenemase genes among clinical isolates of Klebsiella pneumoniae recovered from patients attending a private tertiary hospital in Southwestern Nigeria DOI Creative Commons
Chisom Blossom Onyeji, Seyi Samson Enitan, Olalekan Ademola Kemiki

и другие.

BMC Infectious Diseases, Год журнала: 2024, Номер 24(1)

Опубликована: Сен. 13, 2024

Язык: Английский

Процитировано

0
A systematic review and meta-analysis of carbapenem-resistant Enterobacteriaceae in West Africa DOI Creative Commons
Namwin Siourimè Somda,

Rabbi Nyarkoh,

Fleischer C. N. Kotey

и другие.

BMC Medical Genomics, Год журнала: 2024, Номер 17(1)

Опубликована: Ноя. 12, 2024

In Africa, the problem of carbapenem-resistant Enterobacteriaceae (CRE) is aggravated by many factors. This systematic review attempted to describe current status molecular epidemiology carbapenem resistance in West Africa (WA). Articles published from 16 African countries on were reviewed. An extensive literature search was carried out PubMed, Scopus, Web Science, and Journals Online (AJOL) using specific keywords. The meta-analysis forest plots major pathogens genes done Open Meta-Analyst, Task Order # 2 software. data analysed binary random model effects DerSimonian-Laird method at a 95% confidence interval. Of 431 articles found our initial search, 60 (13.92%) considered suitable for inclusion. Only seven formed part analysis, Nigeria (23/60), Ghana (19/60), Burkina Faso (7/60), Senegal (6/60), Benin (2/60), Mali Togo (1/60). Also, 80% (48/60) studies used clinical samples, 16.67% (10/60) environmental 3.33% (2/60) animal samples. average prevalence highest Acinetobacter baumannii (18.6%; CI = 14.0-24.6, I2 97.9%, p < 0.001), followed Pseudomonas aeruginosa (6.5%; 3.1–13.4, 96.52%, Klebsiella pneumoniae (5.8%; 4.2–7.9, 98.06%, 0.001) Escherichia coli (4.1%; 2.2–7.7, 96.68%, 0.001). blaNDM gene 10.6% (95% 7.9–14.3, 98.2%, 3.9% CI: 1.8–8.3, 96.73%, blaVIM 3.1% 1.7–5.8, 91.69%, blaOXA-48. K. pneumoniae, E. coli, A. baumannii, P. are main CRE with blaNDM, blaVIM, blaOXA-48 being predominant genes. view these results, ongoing surveillance combined antimicrobial stewardship improved, laboratory detection methods, adherence infection control practices will be needed spread CRE.

Язык: Английский

Процитировано

0
Prevalence and molecular epidemiology of carbapenem resistance in Asia: A systematic review and meta-analysis DOI Creative Commons
Nishadi Jayathilaka,

Shehana Denagamagei,

Dilini Nakkawita

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Дек. 18, 2024

Abstract Background Carbapenems are a group of last-resort antibiotics used to treat serious life-threatening infections. The emergence resistance carbapenems is major public health threat. However, comprehensive information on the prevalence and molecular epidemiology carbapenem (CR) among Asian countries lacking. Therefore, we aimed determine CR associated determinants quantitatively countries. Methods In this systematic review meta-analysis, searched published reports in electronic databases such as PubMed, ScienceDirect, Cochrane Library Web Science from 1st January 2014 31st 2024 that fulfilled these criteria; original studies conducted countries, including clinical isolates, English. Data extraction risk bias assessment was performed by two independent reviewers. pooled with 95% confidence interval (CI) computed random effects model. Heterogeneity across determined I2. geographical location, income level, publication year sample size were analysed subgroups. Results We identified 2518 eligible studies, which 37 assessed data 10,433 patients. (PPr) 31.3% (95% CI; 0.22 0.40; I2 = 99.9%; P 0.00). A trend incidence observed 2004–2023, PPr values ranging 7.4–50.6%. Variation distribution genes observed, blaNDM being most common gene, followed blaOXA blaKPC. Univariate meta–regression analysis indicated did not significantly affect heterogeneity (p < 0.05). Conclusion results suggest surveillance essential reduce burden antibiotic resistance. Mitigating impact infections will safeguard efficacy for future generations further dissemination genes. Systematic registration: This registered at PROSPERO (CRD42024515806).

Язык: Английский

Процитировано

0